2012-003064-47: A Phase 1 study of the body and tumour effects of CUDC-101 in HER2 positive breast cancer patients |
|
|
| Terminated | 2 | 20 | Europe | CUDC-101, CUDC-101, Powder for solution for infusion | Curis, Inc., Curis, Inc. | HER2 positive breast cancer, breast cancer, Diseases [C] - Cancer [C04] | | | | |
